ARA American Renal Associates Holdings Inc.

American Renal Associates Holdings, Inc. Announces Settlement of Shareholder Derivative Litigation

American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading provider of outpatient dialysis services, is pleased to announce that the Company has received preliminary approval of the settlement of a stockholder derivative action brought by Plaintiff Luke Johnson, and pending in the United States District Court for the District of New Jersey (case number No. 19-cv-15812) (the “Johnson Action”). The proposed settlement releases all claims asserted against the Company and the other named defendants in the Johnson Action without any liability or wrongdoing attributed to them. The proposed settlement remains subject to court approval and other customary conditions.

The proposed settlement does not involve a payment by or to ARA and will have no impact on ARA’s financial condition or results of operations. Current shareholders may access a notice describing the proposed settlement and the agreement setting forth its terms on the Company's Investor Relations webpage. Visit for more information.

About American Renal Associates

American Renal Associates (“ARA”) is a leading provider of outpatient dialysis services in the United States. As of June 30, 2020, ARA operated 251 dialysis clinic locations in 27 States and the District of Columbia serving more than 17,300 patients with end stage renal disease. ARA operates principally through a physician partnership model, in which it partners with local nephrologists to develop, own and operate dialysis clinics. ARA's Core Values emphasize taking good care of patients, providing physicians with clinical autonomy and support, hiring the best possible staff and providing best practices management. For more information about American Renal Associates, visit .

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements included in this release, including expectations about the settlement of the Johnson Action are based upon information available to the Company as of the date of this release, which may change. These statements are not guarantees of future performance and actual results could differ materially from the Company's current expectations. Factors that could cause or contribute to such differences include the risks and uncertainties described in “Risk Factors” and “Special Note Regarding Forward-Looking Statements” in our Annual Report on Form 10-K for the year ended December 31, 2019 as well as the possibility that the court may fail to approve the terms of the settlement. The Company assumes no obligation and does not intend to update the forward-looking statements provided, whether as a result of new information, future events or otherwise.

EN
18/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on American Renal Associates Holdings Inc.

 PRESS RELEASE

American Renal Associates Holdings, Inc. Announces Third Quarter 2020 ...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the third quarter ended September 30, 2020. Certain metrics, including those expressed on an adjusted basis, are Non-GAAP financial measures (See “Use of Non-GAAP Financial Measures” and the reconciliation tables further below). Third Quarter 2020 Highlights (all percentage changes compare Q3 2020 to Q3 2019 unless noted): Patient service operati...

 PRESS RELEASE

American Renal Associates Enters Into Definitive Agreement to be Acqui...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA) (“ARA” or the “Company”), a leading provider of outpatient dialysis services, today announced that it has entered into a definitive agreement to be acquired by Innovative Renal Care, LLC (“IRC”), an affiliate of Nautic Partners, LLC (“Nautic”), a middle market private equity firm, in an all-cash transaction that values the Company at an aggregate enterprise valuation of approximately $853 million excluding non-controlling interest. Under the terms of the agreement, ARA shareholders will receive $11.50 per sh...

 PRESS RELEASE

American Renal Associates Holdings, Inc. Announces Settlement of Share...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading provider of outpatient dialysis services, is pleased to announce that the Company has received preliminary approval of the settlement of a stockholder derivative action brought by Plaintiff Luke Johnson, and pending in the United States District Court for the District of New Jersey (case number No. 19-cv-15812) (the “Johnson Action”). The proposed settlement releases all claims asserted against the Company and the other named defendants in the Johnson Action without any liability o...

 PRESS RELEASE

American Renal Associates Holdings, Inc. Announces Second Quarter 2020...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the second quarter ended June 30, 2020. The Company also provided an update on its COVID-19 impact and affirmed its 2020 Adjusted EBITDA less noncontrolling interests (“Adjusted EBITDA-NCI”) Outlook. These updates are highlighted later in this release. Certain metrics, including those expressed on an adjusted basis, are Non-GAAP financial measures ...

 PRESS RELEASE

American Renal Associates Holdings, Inc. Announces Second Quarter 2020...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA), a leading kidney care and dialysis services provider focused on partnering with local nephrologists, announced today that it will release its second quarter 2020 earnings results after the market close on Monday, August 10, 2020, to be followed by a conference call on Tuesday, August 11, 2020 at 9:00 a.m. (Eastern Time). The conference call can be accessed live over the phone by dialing (877) 407-8029, or for international callers (201) 689-8029. A replay will be available one hour after the call and can ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch